Literature DB >> 32299786

Altered chemokine profile in Refractory Mycoplasma pneumoniae pneumonia infected children.

Yi-Chen Lee1, Chih-Hao Chang2, Wei-Ju Lee3, Ta-Yu Liu1, Chih-Min Tsai1, Ti-An Tsai1, Chang-Ku Tsai1, Kuang-Che Kuo1, Chih-Cheng Chen1, Chen-Kuang Niu1, Hong-Ren Yu4.   

Abstract

BACKGROUND: Mycoplasma pneumoniae is one of the major pathogens causing community-acquired pneumonia in children. Although usually self-limited, Mycoplasma pneumoniae pneumonia (MPP) may lead to complicated morbidity that can even be life-threatening. Upon MPP infection, alveolar macrophage becomes attracted and activated and will induce subsequent cytokine and chemokine reaction. Refractory Mycoplasma pneumoniae pneumonia (RMPP) is manifested by clinical or radiological deterioration despite proper antibiotic therapy. RMPP is characterized with excessive inflammation and may need subsequent glucocorticoid treatment. AIM: The aim of this study was to investigate the change of plasma chemokines in non-refractory Mycoplasma pneumoniae pneumonia (NRMPP) and RMPP before and after antibiotic or methylprednisolone treatment.
METHOD: A total of 42 children with MPP were enrolled in this study. Plasma specimens were collected at admission and one to two weeks after antibiotic or methylprednisolone treatment with declined fever. Plasma specimens were then indicated to chemokines detection.
RESULTS: Mycoplasma pneumoniae pneumonia altered the chemokine profile through the observation of decreased plasma M1 related chemokines (CCL2, CCL8 and CXCL10) and increased M2 related chemokines (CCL17 and CCL22) after treatment.When the patients were divided into RMPP and NRMPP groups and the chemokines before treatment were compared, the RMPP group showed higher CXCL10 but lower CCL3 and CCL11 than the NRMPP group.
CONCLUSION: Unique changes in macrophage related chemokines is observed in the course of MPP infection. NRMPP and RMPP infection in children showed distinct manifestation in chemokine profiles.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Chemokine; Children; Mycoplasma pneumonia; Refractory Mycoplasma pneumoniae pneumonia

Mesh:

Substances:

Year:  2020        PMID: 32299786     DOI: 10.1016/j.jmii.2020.03.030

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

1.  A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severe Mycoplasma pneumoniae pneumonia.

Authors:  Ruochen Zhu; Song Mao; Wenjing Shi; Liangxia Wu; Jianhua Zhang
Journal:  Transl Pediatr       Date:  2022-05

2.  Refractory Mycoplasma Pneumonia in Children: A Systematic Review and Meta-analysis of Laboratory Features and Predictors.

Authors:  Wanjie Huang; Xianhong Xu; Wenqi Zhao; Qi Cheng
Journal:  J Immunol Res       Date:  2022-06-26       Impact factor: 4.493

3.  [Value of chitinase-like protein YKL-40 in bronchoalveolar lavage fluid for predicting refractory Mycoplasma pneumoniae pneumonia in children].

Authors:  Li-Lin Huang; Dong-Ping Huang; Ling-Long Lu; Jing Li; Shu-Mei Peng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-05

4.  Development of a Nomogram for Predicting Refractory Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Fangfang Shen; Chunjuan Dong; Tongqiang Zhang; Changjiang Yu; Kun Jiang; Yongsheng Xu; Jing Ning
Journal:  Front Pediatr       Date:  2022-02-25       Impact factor: 3.418

5.  Efficacy of Gamma Globulin Combined with Azithromycin Sequential Therapy in the Treatment of RMPP and Its Effect on Th1/Th2 Cytokine Levels.

Authors:  Jie Qi; Fang Jia; Hui Tian; Shengmei Yang
Journal:  Comput Math Methods Med       Date:  2022-07-20       Impact factor: 2.809

6.  Ribosomal RNA‑depleted RNA sequencing reveals the pathogenesis of refractory Mycoplasma pneumoniae pneumonia in children.

Authors:  Feng Huang; Huifeng Fan; Diyuan Yang; Junsong Zhang; Tingting Shi; Dongwei Zhang; Gen Lu
Journal:  Mol Med Rep       Date:  2021-09-03       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.